当前位置:首页 - 行情中心 - 山河药辅(300452) - 财务分析 - 利润表

山河药辅

(300452)

  

流通市值:26.34亿  总市值:31.09亿
流通股本:1.99亿   总股本:2.34亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入521,648,673.91261,391,437.57942,795,401.5696,502,709.9
  营业收入521,648,673.91261,391,437.57942,795,401.5696,502,709.9
二、营业总成本426,933,973.05210,786,022.15777,028,261.41570,301,274.26
  营业成本354,428,231.28176,999,425.7643,431,346.38474,492,384.08
  税金及附加5,142,096.062,843,413.419,850,333.137,595,970.81
  销售费用16,214,288.787,847,580.9830,550,967.4421,355,478.13
  管理费用17,902,419.877,849,230.937,777,582.8226,092,398.18
  研发费用23,935,510.4510,667,979.8342,274,314.7531,868,425.59
  财务费用9,311,426.614,578,391.3313,143,716.898,896,617.47
  其中:利息费用6,823,429.313,373,630.8213,144,812.279,771,583.05
  其中:利息收入1,457,148.46793,649.451,534,865.17962,224.76
三、其他经营收益
  加:公允价值变动收益2,112,295.48-3,117,707.865,918,220.781,236,270.72
  加:投资收益9,064,742.524,627,159.2813,350,434.6611,886,128.19
  资产处置收益-759,372.2-162,386.95-960,070.63-371,211.49
  资产减值损失(新)---58,508.45-
  信用减值损失(新)16.116.1160.21-9,841.5
  其他收益5,532,227.342,467,378.1615,093,099.1911,315,117.29
四、营业利润110,664,610.154,419,874.15199,110,475.85150,257,898.85
  加:营业外收入272,941.879,486.13416,421.54301,633.55
  减:营业外支出40,703.3538,454.25841,945.4194,934.45
五、利润总额110,896,848.5554,460,906.03198,684,951.99150,364,597.95
  减:所得税费用13,800,980.736,985,471.0625,510,251.7317,827,427.52
六、净利润97,095,867.8247,475,434.97173,174,700.26132,537,170.43
(一)按经营持续性分类
  持续经营净利润97,095,867.8247,475,434.97173,174,700.26132,537,170.43
(二)按所有权归属分类
  归属于母公司股东的净利润96,189,158.3147,059,919.32176,552,467.48132,563,910.37
  少数股东损益906,709.51415,515.65-3,377,767.22-26,739.94
  扣除非经常损益后的净利润86,705,204.4145,532,664.34159,131,785.44119,577,509.58
七、每股收益
  (一)基本每股收益0.410.20.750.57
  (二)稀释每股收益0.390.190.730.55
九、综合收益总额97,095,867.8247,475,434.97173,174,700.26132,537,170.43
  归属于母公司股东的综合收益总额96,189,158.3147,059,919.32176,552,467.48132,563,910.37
  归属于少数股东的综合收益总额906,709.51415,515.65-3,377,767.22-26,739.94
公告日期2026-08-222026-04-232026-04-232025-10-21
审计意见(境内)标准无保留意见
TOP↑